Clinical and Experimental Vaccine Research

  • 제11권2호
  • /
  • Pages.222-225
  • /
  • 2022
  • /
  • 2287-3651(pISSN)
  • /
  • 2287-366X(eISSN)
대한백신학회 (The Korean Vaccine Society)
권호 표지
DOI QR코드

DOI QR Code

Epstein-Barr virus reactivation after COVID-19 vaccination in a young immunocompetent man: a case report

  • Astrid Herzum (Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS) ;
  • Ilaria Trave (Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS) ;
  • Federica D'Agostino (Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS) ;
  • Martina Burlando (Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS) ;
  • Emanuele Cozzani (Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS) ;
  • Aurora Parodi (Department of Dermatology, Di.S.Sal., University of Genoa, San Martino Polyclinic Hospital IRCCS)
  • 투고 : 2022.01.15
  • 심사 : 2022.04.30
  • 발행 : 2022.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

We present the case of a 24-year-old Caucasian man, who developed a scaly erythematous skin rash after the second dose of coronavirus disease 2019 (COVID-19) vaccination with Comirnaty (BNT162b2, BioNTech/Pfizer; Pfizer, New York, NY, USA) and proved positive for Epstein-Barr virus (EBV) reactivation. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines have been associated with an up-regulated T helper type 1-cell response, possibly favoring an immune system imbalance. Also, EBV reactivation has been postulated after COVID-19 vaccination, but only in the immunosuppressed. Noteworthy we report the first case of EBV viral reactivation associated with cutaneous manifestations in an immunocompetent patient after the COVID-19 vaccine.

키워드

참고문헌

  1. Burlando M, Herzum A, Micalizzi C, Cozzani E, Parodi A. Cutaneous reactions to COVID-19 vaccine at the dermatology primary care. Immun Inflamm Dis 2022;10:265-71.
  2. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 2020;586:594-9.
  3. Cyrenne BM, Al-Mohammedi F, DeKoven JG, Alhusayen R. Pityriasis rosea-like eruptions following vaccination with BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol 2021;35:e546-8.
  4. Ciccarese G, Parodi A, Drago F, Herzum A, Drago F. Pityriasis rosea in a patient with retrovirus infection: a reply. Postepy Dermatol Alergol 2018;35:116-7.
  5. Katsikas Triantafyllidis K, Giannos P, Mian IT, Kyrtsonis G, Kechagias KS. Varicella zoster virus reactivation following COVID-19 vaccination: a systematic review of case reports. Vaccines (Basel) 2021;9:1013.
  6. Drago F, Herzum A, Ciccarese G, Broccolo F, Rebora A, Parodi A. Acute pain and postherpetic neuralgia related to Varicella zoster virus reactivation: comparison between typical herpes zoster and zoster sine herpete. J Med Virol 2019;91:287-95.
  7. Tang WR, Hsu CW, Lee CC, et al. A case report of posttransplant lymphoproliferative disorder after AstraZeneca coronavirus disease 2019 vaccine in a heart transplant recipient. Transplant Proc 2021 Sep 30 [Epub]. https://doi.org/10.1016/j.transproceed.2021.09.006.
  8. Ciccarese G, Trave I, Herzum A, Parodi A, Drago F. Dermatological manifestations of Epstein-Barr virus systemic infection: a case report and literature review. Int J Dermatol 2020;59:1202-9.
  9. Sardy M, Wollenberg A, Niedermeier A, Flaig MJ. Genital ulcers associated with Epstein-Barr virus infection (ulcus vulvae acutum). Acta Derm Venereol 2011;91:55-9.
  10. Drago F, Ciccarese G, Rebora A, Parodi A. Human herpesvirus-6, -7, and Epstein-Barr virus reactivation in pityriasis rosea during COVID-19. J Med Virol 2021;93:1850-1.
  11. Lehner GF, Klein SJ, Zoller H, Peer A, Bellmann R, Joannidis M. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit Care 2020;24:657.
  12. Chen J, Dai L, Barrett L, et al. SARS-CoV-2 proteins and anti-COVID-19 drugs induce lytic reactivation of an oncogenic virus. Commun Biol 2021;4:682.
  13. Lankes HA, Fought AJ, Evens AM, Weisenburger DD, Chiu BC. Vaccination history and risk of non-Hodgkin lymphoma: a population-based, case-control study. Cancer Causes Control 2009;20:517-23.
  14. Papakostas D, Stavropoulos PG, Papafragkaki D, Grigoraki E, Avgerinou G, Antoniou C. An atypical case of pityriasis rosea gigantea after influenza vaccination. Case Rep Dermatol 2014;6:119-23.